LUNGevity: Lung Cancer’s Warrior in the Fight Against Misinformation
Linda WengerOnline health content often contains harmful information. Worse, research shows inaccurate data may attract more attention than evidence-based information. Read more
TTLC 2022 gets under way. WCLC registration now open but abstract submission deadline is coming soon. Read more
Taiwan OKs nivolumab IV infusion in some cases. UK approves atezolizumab for NSCLC. European Commission greenlights lorlatinib for advanced ALK-positive disease. Read more
Association of Race with Lung Cancer Risk Among Adults Undergoing Lung Cancer Screening
Christine S. Shusted, MPH+more
Data suggest lung cancer risk scores are not aligned with lung cancer diagnoses in Black patients. Take a closer look at how race influences lung cancer screening. Read more
In the second half of our series on patient-doctor communication, see how medical students are learning the skills they need to better communicate with patients. Read more
Ongoing Research Looks at Optimizing Lung Cancer Screening Programs
Beth Fand IncollingoStudies seek to optimize lung screening by monitoring incidentally detected nodules, delaying some repeat scans, and balancing false positives against delayed diagnosis. Read more
GO2 Foundation for Lung Cancer Aims to Create Resources for Caregivers
Joy CurzioA new survey provides a voice for caregivers regarding the challenges they face and rewards they gain from lung cancer co-survivorship. Read more
In Brief for February 9, 2022
John AustinTTLC goes virtual. Positive results reported for pembrolizumab. GO2 Foundation names Chief of Healthcare Delivery. Read more
Sotorasib earns approval in European Union, Japan. Scotland OKs osimertinib. Read more
As we embark on a third year of practice and research during an ever-evolving, seemingly ceaseless pandemic, we know there will be more changes and challenges in store for the […] Read more